Management of Statin-Intolerant Patients

Introduction to Alternative Therapies

The American College of Cardiology recommends starting with ezetimibe 10 mg daily as first-line therapy for patients who cannot tolerate statins, then adding bempedoic acid if LDL-C targets are not met, and reserving PCSK9 inhibitors for very high-risk patients with persistent LDL-C elevation 1, 2

To confirm true statin intolerance, ensure the patient has attempted at least 2 different statins, including one trial at the lowest FDA-approved dose, and has tried alternative dosing regimens such as every-other-day dosing 1, 2
The patient should have experienced adverse effects that resolved or improved with dose reduction or discontinuation 2

Ezetimibe 10 mg daily should be the initial non-statin therapy for all statin-intolerant patients, reducing LDL-C by approximately 15-20% as monotherapy 1, 3
The American Heart Association suggests that ezetimibe works by inhibiting cholesterol absorption in the small intestine without affecting fat-soluble vitamins or bile acids 1
Ezetimibe has demonstrated cardiovascular outcomes benefit in the IMPROVE-IT trial when added to statin therapy in post-ACS patients 1

If LDL-C targets are not achieved with ezetimibe alone, add bempedoic acid 180 mg daily, which reduces LDL-C by 15-25% with low rates of muscle-related adverse effects 2
Bempedoic acid works upstream from statins in the liver, making it particularly valuable for statin-intolerant patients 2

Reserve PCSK9 inhibitors for very high-risk patients with persistent LDL-C elevation despite ezetimibe and bempedoic acid, reducing LDL-C by approximately 50-60% 1, 2
The American College of Cardiology suggests that PCSK9 inhibitors are well-tolerated in statin-intolerant patients with minimal muscle-related side effects 2

For very high-risk patients, target LDL-C <55 mg/dL with ≥50% reduction from baseline, starting with ezetimibe 10 mg daily and adding bempedoic acid 180 mg daily if not at goal 2
For high-risk patients, target LDL-C <70 mg/dL, starting with ezetimibe 10 mg daily and adding bempedoic acid 180 mg daily if not at goal 2

Consider bile acid sequestrants only if triglycerides are <300 mg/dL and the patient cannot tolerate bempedoic acid, providing modest LDL-C reduction of 15-30% 2, 3
For severe hypertriglyceridemia (>500 mg/dL), consider fibrates to prevent acute pancreatitis 2, 3

Implement intensive dietary therapy alongside pharmacologic treatment, including saturated fats <7% of total calories, trans fatty acids <1% of total calories, and cholesterol <200 mg/day 2, 3
Daily physical activity and weight management are also recommended 3

Don't assume statin intolerance without adequate trials, ensuring at least 2-3 different statins have been attempted, including lowest doses and alternative regimens 1, 2
Don't jump directly to PCSK9 inhibitors, following the stepwise approach (ezetimibe → bempedoic acid → PCSK9 inhibitor) unless dealing with extremely high-risk patients 2